Post-earnings recap
Reported
Thu, Nov 8, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Despite missing on EPS, Arcus Biosciences saw a positive stock reaction, rising 5.15%. This increase may be attributed to investor optimism regarding their clinical trials and future data releases. The lack of revenue and guidance indicates uncertainty, but management's focus on progress could reassure some investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.25 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Overall, management expressed cautious optimism about their pipeline. They focused on the potential of their current projects and the importance of future data.
Management highlighted ongoing progress in clinical trials.
They emphasized the importance of upcoming data releases.